<DOC>
	<DOCNO>NCT01257776</DOCNO>
	<brief_summary>A prospective , multicenter , open , randomize , parallel-group control study two level dose . The study population consist 30 non-diabetic patient critical chronic ischemia least one low limb ( CLI ) without possibility revascularization , result clinically evaluable , , 20 patient include experimental group ( 10 dose level ) 10 control group . In two dose level use study , 15 patient include , randomize experimental group control group accord distribution 2:1 ( 2 patient experimental group 1 control group ) , thus dose level , 10 patient experimental group ( treat mesenchymal cell adipose tissue ) 5 patient control group ( conventional treatment )</brief_summary>
	<brief_title>Human Adipose Derived Mesenchymal Stem Cells Critical Limb Ischemia ( CLI ) Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<criteria>Diabetes , type 1 2 Critical Limb Ischemia ( Rutherford Becker Class II , III IV ) least one limb . No option target limb revascularization . Cancer antecedent last two year Current limb infection limb gangrene</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Critical Limb Ischemia ( CLI )</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Regenerative Therapy</keyword>
</DOC>